Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Colon Cancer

10 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Other

VICCGI99003

08/01/2010

Personalized Prevention of Colorectal Cancer

Other

VICCGI0721

01/09/2007

Vanderbilt Hereditary Colorectal Cancer Registry

Prevention

GIS0820-M

07/09/2013

A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

Supportive Care

VICCGI1549

08/04/2015

PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A randomized controlled pilot study of yoga compared to an attention control in 60 patients receiving chemotherapy

Treatment

VICCGI14109

07/01/2015

An Open-Label Expanded Access Study of TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy

Treatment

VICCGI14104

06/08/2015

Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ? Bevacizumab Versus Placebo Plus FOLFIRI ? Bevacizumab in Previously Untreated Metastatic Colorectal Cancer

Treatment

VICCGI13102

12/09/2014

A Phase II Study of Panitumumab in Combination with FOLFIRI after Progression on FOLFIRI plus Bevacizumab in KRAS and NRAS Wild Type Metastatic Colorectal Cancer

Treatment

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Treatment

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers